Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons
Stockholm, Sweden March 22, 2024 – BioArctic AB:s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Oral Explanation scheduled for March 19 at the Committee for Medicinal Products for Human Use (CHMP) for lecanemab, which is currently under review by the European Medicines Agency (EMA), did not take place due to procedural reasons at EMA.On March 14, 2024, the Court of Justice of the European Union ruled on the organization of EMA’s Scientific Advisory Groups (SAGs) attendance . The